Blarcamesine sustains benefits in early Alzheimer’s over year: Data
Experimental blarcamesine (Anavex 2-73) was able to slow cognitive and functional decline in early Alzheimer’s patients over a year, data show.| Alzheimer's News Today
Category archive page for Columns.| Alzheimer's News Today
Experimental blarcamesine (Anavex 2-73) was able to slow cognitive and functional decline in early Alzheimer’s patients over a year, data show.| Alzheimer's News Today
Zunveyl, a new oral mild-to-moderate Alzheimer's therapy, showed bioequivalence to galanotamine but fewer GI issues like nausea in studies.| Alzheimer's News Today
